pipeline-prospector-insert
X

Find Drugs for Trauma (Emergency, Injury, Surgery) in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Wnt Activating Antibodies

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Surrozen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 29, 2020

            Details:

            Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine,Cannabidiol

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Champignon

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 08, 2020

            Details:

            Champignon Brands has selected Toronto-based Dalriada Drug Discovery Inc.to advance its new chemical entity IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KB-1801

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 27, 2020

            Details:

            This research shows that the activation of P2Y14 receptors initiates the secretion of proinflammatory factors within the kidney and rapidly causes the recruitment of neutrophils and monocytes, starting the inflammatory cycle.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HST 004

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the ASCO 2020.

            Liverpool School of Tropical Medicine

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dimercaprol

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            Study found dimercaprol and its derivative 2,3-dimercapto-1-propanesulfonic acid (DMPS) were found to inhibit the in vitro activity of snake venom enzymes that rely on zinc ions to function.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PLX-R18

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            The decision is based on BARDA’s technical considerations as determined by a Technical Evaluation Panel. Other factors included BARDA’s current strategic needs, availability of funds and resources.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): rhNELL-1

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.